Preliminary Efficacy, Safety Data Drive Further Exploration of Mezigdomide-Based Combinations in R/R Myeloma @ash.hematology.org #ASH24 #mmsm www.onclive.com/view/prelimi...
Preliminary Efficacy, Safety Data Drive Further Exploration of Mezigdomide-Based Combinations in R/R Myeloma
David S. Siegel, MD, PhD, discusses early safety and efficacy data that support further development of mezigdomide-based combinations in multiple myeloma.
www.onclive.com
January 17, 2025 at 3:22 PM
Preliminary Efficacy, Safety Data Drive Further Exploration of Mezigdomide-Based Combinations in R/R Myeloma @ash.hematology.org #ASH24 #mmsm www.onclive.com/view/prelimi...
“There are relatively few accessible therapeutic options for patients whose multiple myeloma has returned or stopped responding to current standard treatments. These results support mezigdomide, a potent and novel oral therapy, as a new standard of care for RRMM across multiple settings.”
May 29, 2026 at 9:48 PM
“There are relatively few accessible therapeutic options for patients whose multiple myeloma has returned or stopped responding to current standard treatments. These results support mezigdomide, a potent and novel oral therapy, as a new standard of care for RRMM across multiple settings.”
Wrapping up day one of #ASCO26 with Paul G. Richardson, MD, sharing phase 3 trial results for patients with relapsed or refractory multiple myeloma, the addition of the oral drug mezigdomide to standard treatment with carfilzomib and dexamethasone markedly improved progression-free survival.
May 29, 2026 at 9:48 PM
Wrapping up day one of #ASCO26 with Paul G. Richardson, MD, sharing phase 3 trial results for patients with relapsed or refractory multiple myeloma, the addition of the oral drug mezigdomide to standard treatment with carfilzomib and dexamethasone markedly improved progression-free survival.
Bristol Myers Squibb said on Friday that its experimental oral drug mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed or not responded to other treatments.
Bristol Myers drug delays myeloma progression in hard to treat patients
Bristol Myers Squibb said on Friday that its experimental oral drug mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed or not responded to other treatments.
reut.rs
May 29, 2026 at 12:10 PM
Bristol Myers Squibb said on Friday that its experimental oral drug mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed or not responded to other treatments.
Dr. Paul Richardson of @danafarber.bsky.social presents results from SUCCESSOR-2 study showing the oral drug mezigdomide markedly improved PFS in patients w/relapsed or refractory multiple myeloma. Results support this novel therapy as a possible new standard of care for RRMM. #ASCO26 bit.ly/4wUzw6z
May 29, 2026 at 5:30 PM
Dr. Paul Richardson of @danafarber.bsky.social presents results from SUCCESSOR-2 study showing the oral drug mezigdomide markedly improved PFS in patients w/relapsed or refractory multiple myeloma. Results support this novel therapy as a possible new standard of care for RRMM. #ASCO26 bit.ly/4wUzw6z
Where do CELMoDs, including mezigdomide and iberdomide, fit in the myeloma treatment landscape? Watch the discussion below. 👇
sohoinsider.com/roundtable-d...
sohoinsider.com/roundtable-d...
Where do CELMoDs, including mezigdomide and iberdomide, fit in the myeloma treatment landscape?
The roundtable panelists discuss where CELMoDs, including mezigdomide and iberdomide, fit in the multiple myeloma treatment landscape. The panel evaluates the distinct toxicity profiles of these…
sohoinsider.com
September 19, 2026 at 9:30 PM
Where do CELMoDs, including mezigdomide and iberdomide, fit in the myeloma treatment landscape? Watch the discussion below. 👇
sohoinsider.com/roundtable-d...
sohoinsider.com/roundtable-d...
Addition of mezigdomide to myeloma treatment regimens shows promise for relapsed/refractory disease.
Addition of mezigdomide to myeloma treatment regimens shows promise for relapsed/refractory disease
By: Kerri Fitzgerald Results from the phase 1/2 CA057-003 study showed early efficacy and safety with the addition of mezigdomide to novel combinations for relapsed or refractory multiple myeloma…
sohoinsider.com
September 10, 2025 at 4:50 AM
Addition of mezigdomide to myeloma treatment regimens shows promise for relapsed/refractory disease.
Could a new standard of care be emerging for R/R #multiplemyeloma? At #ASCO26, Dr Richardson highlights phase III SUCCESSOR-2 data showing that mezigdomide plus carfilzomib and dexamethasone significantly improved progression-free survival. ecancer.org/en/video/129...
Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma - ecancer
At ASCO 2026, Dr Paul Richardson talks to ecancer about results from the phase III SUCCESSOR-2 study evaluating mezigdomide plus carfilzomib and dexamethasone i
ecancer.org
June 1, 2026 at 3:29 PM
Could a new standard of care be emerging for R/R #multiplemyeloma? At #ASCO26, Dr Richardson highlights phase III SUCCESSOR-2 data showing that mezigdomide plus carfilzomib and dexamethasone significantly improved progression-free survival. ecancer.org/en/video/129...
🆕 #ASCO26! 🚨 The Phase 3 SUCCESSOR-2 trial shows that adding oral mezigdomide to Kd nearly doubles progression-free survival in RRMM.
📈 Median PFS: 18.0 mos vs 8.3 mos
📉 52% reduction in risk of progression/death (HR 0.48)
A major leap for triple-class exposed patients. 🧬
🔗 https://bit.ly/4u7KJhA
📈 Median PFS: 18.0 mos vs 8.3 mos
📉 52% reduction in risk of progression/death (HR 0.48)
A major leap for triple-class exposed patients. 🧬
🔗 https://bit.ly/4u7KJhA
Mezigdomide Shows Survival Benefit in RRMM - Hematology Advisor
Researchers compared combination mezigdomide with carfilzomib and dexamethasone against carfilzomib and dexamethasone in patients with RRMM.
bit.ly
May 31, 2026 at 8:45 PM
🆕 #ASCO26! 🚨 The Phase 3 SUCCESSOR-2 trial shows that adding oral mezigdomide to Kd nearly doubles progression-free survival in RRMM.
📈 Median PFS: 18.0 mos vs 8.3 mos
📉 52% reduction in risk of progression/death (HR 0.48)
A major leap for triple-class exposed patients. 🧬
🔗 https://bit.ly/4u7KJhA
📈 Median PFS: 18.0 mos vs 8.3 mos
📉 52% reduction in risk of progression/death (HR 0.48)
A major leap for triple-class exposed patients. 🧬
🔗 https://bit.ly/4u7KJhA
Imagine cutting the risk of disease progression or death by over 50% in a tough cancer battle. New findings from ASCO reveal a breakthrough in myeloma treatment that could change lives. How could this redefine patient care? 🌟
ASCO 2026: BMS's mezigdomide reduces risk in myeloma by over 50%, and Pfizer's lorlatinib maintains 55% progression-free survival at 7 years - Sinaptica
The 62nd annual meeting of the American Society of Clinical Oncology (ASCO), held on May 29 in Chicago, opened with two results that redefine the treatment stan
sinapti.ca
May 29, 2026 at 10:12 PM
Imagine cutting the risk of disease progression or death by over 50% in a tough cancer battle. New findings from ASCO reveal a breakthrough in myeloma treatment that could change lives. How could this redefine patient care? 🌟
🚨 Latest #Phase3 Trial Update!
🔷 Bristol Myers Squibb’s Phase 3 SUCCESSOR-2 trial reports positive outcomes with oral Mezigdomide in relapsed or refractory multiple myeloma.
🔷 Bristol Myers Squibb’s Phase 3 SUCCESSOR-2 trial reports positive outcomes with oral Mezigdomide in relapsed or refractory multiple myeloma.
March 10, 2026 at 2:06 PM
🚨 Latest #Phase3 Trial Update!
🔷 Bristol Myers Squibb’s Phase 3 SUCCESSOR-2 trial reports positive outcomes with oral Mezigdomide in relapsed or refractory multiple myeloma.
🔷 Bristol Myers Squibb’s Phase 3 SUCCESSOR-2 trial reports positive outcomes with oral Mezigdomide in relapsed or refractory multiple myeloma.
#EHA2025 | Paul Richardson of @danafarber.bsky.social comments on the effectiveness of mezigdomide in novel combinations for reactivating the immune system in patients with R/R #MultipleMyeloma:
🎥 buff.ly/3MFWK1V
#MMSM #Myeloma #HemOnc #BloodSky #HemeSky #MedSky
🎥 buff.ly/3MFWK1V
#MMSM #Myeloma #HemOnc #BloodSky #HemeSky #MedSky
July 28, 2025 at 4:04 PM
#EHA2025 | Paul Richardson of @danafarber.bsky.social comments on the effectiveness of mezigdomide in novel combinations for reactivating the immune system in patients with R/R #MultipleMyeloma:
🎥 buff.ly/3MFWK1V
#MMSM #Myeloma #HemOnc #BloodSky #HemeSky #MedSky
🎥 buff.ly/3MFWK1V
#MMSM #Myeloma #HemOnc #BloodSky #HemeSky #MedSky
A Next-Generation Cereblon E3 Ligase Modulator in Ph. III Clinical Trials for Multiple Myeloma
This article reviews the fascinating science behind CELMoDs, detailing the discovery, optimization, preclinical findings, and current clinical evaluation of mezigdomide
Read more: drughunters.com/4i83NHe
This article reviews the fascinating science behind CELMoDs, detailing the discovery, optimization, preclinical findings, and current clinical evaluation of mezigdomide
Read more: drughunters.com/4i83NHe
March 3, 2025 at 9:57 PM
A Next-Generation Cereblon E3 Ligase Modulator in Ph. III Clinical Trials for Multiple Myeloma
This article reviews the fascinating science behind CELMoDs, detailing the discovery, optimization, preclinical findings, and current clinical evaluation of mezigdomide
Read more: drughunters.com/4i83NHe
This article reviews the fascinating science behind CELMoDs, detailing the discovery, optimization, preclinical findings, and current clinical evaluation of mezigdomide
Read more: drughunters.com/4i83NHe
Is targeted protein degradation ready to compete with established cancer therapies? The latest Phase 3 data suggest the answer may be yes. Results from the SUCCESSOR-2 trial have put mezigdomide in the spotlight.
Article link 👇
#MultipleMyeloma #Oncology #ClinicalTrials
Article link 👇
#MultipleMyeloma #Oncology #ClinicalTrials
July 20, 2026 at 6:47 PM
Is targeted protein degradation ready to compete with established cancer therapies? The latest Phase 3 data suggest the answer may be yes. Results from the SUCCESSOR-2 trial have put mezigdomide in the spotlight.
Article link 👇
#MultipleMyeloma #Oncology #ClinicalTrials
Article link 👇
#MultipleMyeloma #Oncology #ClinicalTrials
🔷 This marks the first positive Phase III trial for the oral CELMoD Mezigdomide, with a safety profile consistent with prior studies.
🔗 Read more: bit.ly/ONCOnews10Ma...
#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #ClinicalTrials #Phase3Trial
🔗 Read more: bit.ly/ONCOnews10Ma...
#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #ClinicalTrials #Phase3Trial
ONCOassist Universal Link
Opening ONCOassist app...
bit.ly
March 10, 2026 at 2:06 PM
🔷 This marks the first positive Phase III trial for the oral CELMoD Mezigdomide, with a safety profile consistent with prior studies.
🔗 Read more: bit.ly/ONCOnews10Ma...
#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #ClinicalTrials #Phase3Trial
🔗 Read more: bit.ly/ONCOnews10Ma...
#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #ClinicalTrials #Phase3Trial
Thank you so much to David Siegel, MD, of John Theurer Cancer Center, for discussing his research into the use of mezigdomide in relapsed/refractory myeloma! Check back on www.onclive.com/conference/ash to hear his insights on the CA057-003 trial. @ash-hematology.bsky.social #ASH24
December 8, 2024 at 12:44 AM
Thank you so much to David Siegel, MD, of John Theurer Cancer Center, for discussing his research into the use of mezigdomide in relapsed/refractory myeloma! Check back on www.onclive.com/conference/ash to hear his insights on the CA057-003 trial. @ash-hematology.bsky.social #ASH24
#WIMMReads 🧪
In two new Blood studies, researchers including the Thomas Milne Group at the #MRCWIMM show that the drug mezigdomide can strengthen #cancer fighting immune cells and improve next generation immunotherapies.
Read more 👇
#CancerResearch #Immunotherapy #AcademicSky @medsci.ox.ac.uk
In two new Blood studies, researchers including the Thomas Milne Group at the #MRCWIMM show that the drug mezigdomide can strengthen #cancer fighting immune cells and improve next generation immunotherapies.
Read more 👇
#CancerResearch #Immunotherapy #AcademicSky @medsci.ox.ac.uk
Reversing T cell exhaustion improves effectiveness of myeloma immunotherapies
Researchers at the Icahn School of Medicine at Mount Sinai, Bristol Myers Squibb (BMS), and the University of Oxford have discovered a way to give worn-out immune cells a second wind in the fight agai...
www.imm.ox.ac.uk
May 21, 2026 at 8:56 AM
#WIMMReads 🧪
In two new Blood studies, researchers including the Thomas Milne Group at the #MRCWIMM show that the drug mezigdomide can strengthen #cancer fighting immune cells and improve next generation immunotherapies.
Read more 👇
#CancerResearch #Immunotherapy #AcademicSky @medsci.ox.ac.uk
In two new Blood studies, researchers including the Thomas Milne Group at the #MRCWIMM show that the drug mezigdomide can strengthen #cancer fighting immune cells and improve next generation immunotherapies.
Read more 👇
#CancerResearch #Immunotherapy #AcademicSky @medsci.ox.ac.uk
We've recapped days 1 and 2 of #IMS26 @myeloma-society.bsky.social. Stay tuned for day 3!
Day 1: www.targetedonc.com/view/ims-202...
Day 2: www.targetedonc.com/view/ims-day...
Day 1: www.targetedonc.com/view/ims-202...
Day 2: www.targetedonc.com/view/ims-day...
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.
www.targetedonc.com
September 25, 2026 at 10:56 AM
We've recapped days 1 and 2 of #IMS26 @myeloma-society.bsky.social. Stay tuned for day 3!
Day 1: www.targetedonc.com/view/ims-202...
Day 2: www.targetedonc.com/view/ims-day...
Day 1: www.targetedonc.com/view/ims-202...
Day 2: www.targetedonc.com/view/ims-day...
CELMoDs in multiple myeloma: a decade of progress. Dr. Ajay Nooka reviews the clinical development of iberdomide and mezigdomide for #SOHO2026
Read more here: sohoinsider.com/news/celmods...
Read more here: sohoinsider.com/news/celmods...
CELMoDs in multiple myeloma: a decade of progress
The first- and second-generation immunomodulatory drugs (IMiDs) have fundamentally transformed the treatment landscape of multiple myeloma (MM) over the past two decades. Lenalidomide combinations…
sohoinsider.com
September 12, 2026 at 3:26 PM
CELMoDs in multiple myeloma: a decade of progress. Dr. Ajay Nooka reviews the clinical development of iberdomide and mezigdomide for #SOHO2026
Read more here: sohoinsider.com/news/celmods...
Read more here: sohoinsider.com/news/celmods...
🎙️ Just published a new episode of Blood Podcast: Better Together: Adding daratumumab for AL Amyloidosis and and Mezigdomide for MM. Have a listen:
Better Together: Adding daratumumab for AL Amyloidosis and and Mezigdomide for MM
In this week's episode, Blood editor Laurie Sehn interviews Drs....
bloodpodcast.transistor.fm
August 27, 2026 at 6:24 PM
🎙️ Just published a new episode of Blood Podcast: Better Together: Adding daratumumab for AL Amyloidosis and and Mezigdomide for MM. Have a listen:
At #EHA2026, Prof Meletios Dimopoulos reports phase 3 SUCCESSOR-2 results showing mezigdomide plus carfilzomib and dexamethasone significantly improved progression free survival, with higher and deeper responses in relapsed or refractory multiple myeloma, with manageable safety.
August 5, 2026 at 4:01 PM
At #EHA2026, Prof Meletios Dimopoulos reports phase 3 SUCCESSOR-2 results showing mezigdomide plus carfilzomib and dexamethasone significantly improved progression free survival, with higher and deeper responses in relapsed or refractory multiple myeloma, with manageable safety.
[Comment] Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?
arc-codex.com
July 19, 2026 at 5:49 AM
[Comment] Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?
🌟 This week's #OncFive 🌟:
🎗️ FDA clears gedatolisib in select PIK3CA WT mBC
🧬 Selpercatinib full approval in RET fusion+ tumors
🚫 3rd CRL for rivoceranib/camrelizumab in 1L HCC
🩸 NDA accepted for mezigdomide combo in r/r myeloma
🟡 Fast track for SOT109 in CRC
🔗: www.onclive.com/view/the-onc...
🎗️ FDA clears gedatolisib in select PIK3CA WT mBC
🧬 Selpercatinib full approval in RET fusion+ tumors
🚫 3rd CRL for rivoceranib/camrelizumab in 1L HCC
🩸 NDA accepted for mezigdomide combo in r/r myeloma
🟡 Fast track for SOT109 in CRC
🔗: www.onclive.com/view/the-onc...
The OncFive: Top Oncology Articles for the Week of 7/12 | OncLive
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
www.onclive.com
July 18, 2026 at 7:24 PM
🌟 This week's #OncFive 🌟:
🎗️ FDA clears gedatolisib in select PIK3CA WT mBC
🧬 Selpercatinib full approval in RET fusion+ tumors
🚫 3rd CRL for rivoceranib/camrelizumab in 1L HCC
🩸 NDA accepted for mezigdomide combo in r/r myeloma
🟡 Fast track for SOT109 in CRC
🔗: www.onclive.com/view/the-onc...
🎗️ FDA clears gedatolisib in select PIK3CA WT mBC
🧬 Selpercatinib full approval in RET fusion+ tumors
🚫 3rd CRL for rivoceranib/camrelizumab in 1L HCC
🩸 NDA accepted for mezigdomide combo in r/r myeloma
🟡 Fast track for SOT109 in CRC
🔗: www.onclive.com/view/the-onc...
Feed: "SOHO Insider"
By: Leah Sherwood on Tuesday, July 14, 2026
By: Leah Sherwood on Tuesday, July 14, 2026
FDA accepts NDA for mezigdomide combo in relapsed or refractory myeloma
The US FDA accepted an NDA for mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
sohoinsider.com
July 14, 2026 at 9:02 AM
Feed: "SOHO Insider"
By: Leah Sherwood on Tuesday, July 14, 2026
By: Leah Sherwood on Tuesday, July 14, 2026
FDA accepts NDA for mezigdomide combo in relapsed or refractory myeloma
sohoinsider.com/news/fda-acc...
sohoinsider.com/news/fda-acc...
FDA accepts NDA for mezigdomide combo in R/R myeloma
The US FDA accepted an NDA for mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
sohoinsider.com
July 14, 2026 at 2:13 AM
FDA accepts NDA for mezigdomide combo in relapsed or refractory myeloma
sohoinsider.com/news/fda-acc...
sohoinsider.com/news/fda-acc...